Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing
Clinical Pharmacology and Therapeutics , Volume 98 - Issue 1 p. 19- 24
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased doseâ djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
|Clinical Pharmacology and Therapeutics|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Birdwell, K.A, Decker, B, Barbarino, J.M, Peterson, J.F, Stein, C.M, Sadee, W, … MacPhee, I.A.M. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clinical Pharmacology and Therapeutics, 98(1), 19–24. doi:10.1002/cpt.113